Heterogeneity of the roles of leukotriene and thromboxane A2 receptor antagonists in the treatment of moderate to severe asthma

Clinical and Experimental Allergy Reviews

Volumn 1, Issue 3, 2001, Pages 280-286

  Tamaoki, J ^a   Isono, K ^a   Nagano, Y ^a   Tagaya, E ^a   Taira, M ^a   Nagai, A ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0038434000     PISSN: 14729725     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1472-9725.2001.t01-1-00015.x     Document Type: Article

References (24)

1. Wenzel SE. Arachidonic acid metabolites: mediators of inflammation in asthma. Pharmacotherapy 1997; 17:3S-12S.
2. Henderson WR. Role of leukotrienes in asthma. Ann Allergy 1994; 72:272-8.
3. O'Byrne PM. Leukotrienes in the pathogenesis of asthma. Chest 1997; 111:27S-34S.
4. Beasley RC, Featherstone RL, Church MK et al. Effect of a thromboxane receptor antagonist on PGD2 and allergen-induced bronchoconstriction. J Appl Physiol 1989; 66:1685-93.
5. Grossman J, Faiferman I, Dubb JW et al. Results of the first US double-blind, placebo-controlled, multicenter clinical study in asthma with pranlukast, a novel leukotriene receptor antagonist. J Asthma 1997; 34:321-8.
6. Barnes NC, de Jong B, Muyamoto T. Worldwide clinical experience with the first marketed leukotriene receptor antagonist. Chest 1997; 111:52S-60S.
7. 2 receptor antagonist (AA-2414) on bronchial hyperresponsiveness to methacholine in subjects with asthma. J Allergy Clin Immunol 1991; 87:23-7.
8. 2 antagonist, reduces bronchial hyperresponsiveness in asthmatics. Chest 1996; 109:338-42.
9. Drazen JM, Israel E, O'Byrne PM. Treatment of asthma with drugs modifying leukotriene pathway. N Encl J Med 1999; 340:197-206.
10. Obata T, Nambe F, Kitagawa T et al. ONO-1078: An antagonist of leukotrienes. Adv Prostaglandin Thromboxane Leukot Res 1987; 17:540-3.
11. 2 receptor by an anti-asthmatic agent AA-2414. Biol Pharm Bull 1994; 17:383-5.
12. National Asthma Education and Prevention Program. Expert panel report 2: guidelines for the diagnosis and management of asthma. National Institutes of Health publication no. 917-4051. Bethesda, MD: National Institutes of Health, 1991:7-13.
13. Neukirch F, Liard R, Segala C, Korobaeff M, Henry C, Cooreman J. Peak expiratory flow variability and bronchial responsiveness to methacholine. An epidemiologic study in 117 workers. Am Rev Respir Dis 1992; 146:71-5.
14. 4 receptor antagonist, in subjects with bronchial asthma. Am J Respi Crit Care Med 1994; 150:618-23.
15. Reiss TF, Chervinsky P, Dockhorn RJ, Shingo S, Scidenberg B, Edwards TB. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Arch Intern Med 1998; 158:1213-20.
16. Barnes NC, Pujet JC. Pranlukast, a novel leukotriene receptor antagonist: results of the first European, placebo controlled, multicentre clinical study in asthma. Thorax 1997; 52:523-7.
17. Nakamura Y, Hoshino M, Sim JJ, Ishii K, Hosaka K, Sakamoto T. Effect of the leukotriene receptor antagonist pranlukast on cellular infiltration in the bronchial mucosa of patients with asthma. Thorax 1998; 53:835-41.
18. Tohda Y, Nakahara H, Kukbo H, Haraguchi R, Fukuoka M, Nakajima S. Effect of ONO-1078 (pranlukast) on cytokine production in peripheral blood mononuclear cells of patients with bronchial asthma. Clin Exp Allergy 1999; 29:1532-6.
19. Tamaoki J, Sakai N, Nakata J et al. Leukotriene antagonist prevents exacerbation of asthma during reduction of high-dose inhaled corticosteroid. Am J Respir Crit Care Med 1997; 155:123540.
20. Yoshida S, Ishizaki Y, Shoji T et al. Effect of pranlukast on bronchial inflammation in patients with asthma. Clin Exp Allergy 2000; 30:1008-14.
21. 2 inhibitors on allergic pulmonary inflammation in mice. Eur Respir J 1998; 11:624-9.
22. 2 in bronchial hyperresponsiveness of asthma. Pulm Pharmacol 1995; 8:251-7.
23. 2 receptor antagonist in asthmatic patients? Respir Med 1999; 93:891-7.
24. 2 antagonist on sputum production and its physicochemical properties in patients with mild to moderate asthma. Chest 2000; 118:73-9.